Siolta Therapeutics, a US-based microbe therapy spinout of University of California, San Francisco, has attracted $30m in a series B round involving medical services provider SymBiosis.
Kirin Health Innovation Fund, a corporate venturing vehicle for food and healthcare products group Kirin Holdings, also participated, as did Seventure’s Health for Life Capital Fund, Global Brain’s GB-VII and private investor Marc Benioff.
Founded in 2016, Siolta Therapeutics hopes to uncover therapeutic microbes capable of treating chronic inflammatory diseases such as allergies.
The company’s lead program, STMC-103H, would treat asthma by alleviating the effects of allergens before they cause disruption in the lungs.
Siolta will put the funding toward conducting phase 2 clinical trials to establish the efficacy of its lead asset, which has been awarded fast-track status by US healthcare regulatory Food and Drug Administrator.
Seventure supplied an undisclosed amount of seed funding to Siolta Therapeutics in 2018 before a previously undisclosed series A round now known to have included Khosla Ventures and Marc Benioff.
– A version of this article first appeared on our sister site, Global Corporate Venturing.

US-based microbe therapy developer Siolta Therapeutics has attracted $30m in a series B round involving medical services provider SymBiosis.

Kirin Health Innovation Fund, a corporate venturing vehicle for food and healthcare products group Kirin Holdings, also participated, as did Seventure’s Health for Life Capital Fund, Global Brain’s GB-VII and private investor Marc Benioff.

Spun out of University of California, San Francisco in 2016, Siolta Therapeutics hopes to uncover therapeutic microbes capable of treating chronic inflammatory diseases such as allergies.

The company’s lead program, STMC-103H, would treat asthma by alleviating the effects of allergens before they cause disruption in the lungs.

Siolta will put the funding toward conducting phase 2 clinical trials to establish the efficacy of its lead asset, which has been awarded fast-track status by US healthcare regulatory Food and Drug Administrator.

Seventure supplied an undisclosed amount of seed funding to Siolta Therapeutics in 2018 before a previously undisclosed series A round now known to have included Khosla Ventures and Marc Benioff.